First Trust NASDAQ Clean Edge Green Energy Idx Fd vs Zoetis Inc — how do they compare? First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $48.32 (market cap $561.25M), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 53.8× First Trust NASDAQ Clean Edge Green Energy Idx Fd's market cap, and Zoetis Inc pays a 2.9% dividend while First Trust NASDAQ Clean Edge Green Energy Idx Fd pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ Clean Edge Green Energy Idx Fd for 50 Days and Zoetis Inc for 70 Days on average.
| QCLN | ZTS | |
|---|---|---|
Market Cap | $561.25M | $30.20B |
Volume | 323,550 | 6,175,327 |
Sector | Sector/Thematic | Health |
52-Week High | $68.47 | $147.53 |
52-Week Low | $41.10 | $69.09 |
Typical Hold Time | 50 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
QCLN trades at $49.44, down 2.62% today but maintains a bullish technical outlook with strong moving average support. The clean energy ETF benefits from geopolitical tensions accelerating renewable energy adoption globally. Recent news highlights increased data center energy demand and political focus on clean energy policies as key growth catalysts.
The ETF's performance remains tied to U.S. political outcomes and federal energy policy, with recent outperformance against major indices. Key risks include policy uncertainty and market volatility, while institutional interest grows amid global energy security concerns and the ongoing energy transition.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Trailing returns across standard periods
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →